These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15269321)

  • 1. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 2. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab in colon cancer.
    Costa AF; Sander GB; Picon PD
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
    [No Abstract]   [Full Text] [Related]  

  • 4. Cetuximab in colon cancer.
    Martin MJ
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
    [No Abstract]   [Full Text] [Related]  

  • 5. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
    Li J
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Normanno N; Tejpar S; Ciardiello F
    J Natl Cancer Inst; 2010 Apr; 102(8):573; author reply 573-5. PubMed ID: 20305131
    [No Abstract]   [Full Text] [Related]  

  • 7. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
    Vincenzi B; Santini D; Tonini G
    J Clin Oncol; 2006 Apr; 24(12):1957; author reply 1957-8. PubMed ID: 16622275
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
    Chu E
    Clin Colorectal Cancer; 2008 May; 7(3):162. PubMed ID: 18621632
    [No Abstract]   [Full Text] [Related]  

  • 9. The price tag on progress--chemotherapy for colorectal cancer.
    Schrag D
    N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
    Vanhoefer U
    Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in colorectal cancer.
    Sharieff W
    N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
    [No Abstract]   [Full Text] [Related]  

  • 13. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
    Owzar K
    J Clin Oncol; 2008 Mar; 26(9):1400-1. PubMed ID: 18349389
    [No Abstract]   [Full Text] [Related]  

  • 14. [Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].
    Yokomizo H; Yoshimatsu K; Osawa G; Matsumoto A; Otani T; Yano Y; Itagaki H; Fujimoto T; Umehara A; Ogawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2249-51. PubMed ID: 21224537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cetuximab].
    Takiuchi H
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient.
    Tonini G; Vincenzi B; Santini D; Olzi D; Lambiase A; Bonini S
    J Natl Cancer Inst; 2005 Apr; 97(8):606-7. PubMed ID: 15840884
    [No Abstract]   [Full Text] [Related]  

  • 18. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Saltz LB
    Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
    [No Abstract]   [Full Text] [Related]  

  • 19. New treatments for colorectal cancer.
    FDA Consum; 2004; 38(3):17. PubMed ID: 15218840
    [No Abstract]   [Full Text] [Related]  

  • 20. [Utilizing synergism].
    Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.